In an early test of its therapy for Parkinson’s disease, International Stem Cell Corp. in San Diego said Monday that the stem cell-based treatment appears to be safe.
The first patient in the Phase 1 clinical trial, conducted in Australia, was treated at the end of July. A checkup three months later found no sign of complications, said Russell Kern, the company’s executive vice president and chief scientific officer.
READ MORE